Pharmaceuticals

Lummy

Lummy released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 182.21 M, actual EPS CNY -0.0142

Lummy to Release FY2026 Q1 Earnings on April 23 After-Market (BJT)

Lummy released FY2025 Annual Earnings on March 18 After-Market (BJT), actual revenue CNY 775.69 M, actual EPS CNY -0.1276

Lummy released FY2025 Q4 earnings on March 18 After-Market (BJT), actual revenue CNY 194.62 M, actual EPS CNY -0.084

Lummy to Release FY2025 Annual Earnings on March 19, 2026, After-Market BJT

Lummy released FY2025 9 Months Earnings on October 21 After-Market (BJT), actual revenue CNY 581.06 M, actual EPS CNY -0.0435

Lummy released FY2025 Q3 earnings on October 21 After-Market (BJT), actual revenue CNY 203.87 M, actual EPS CNY -0.0137

Lummy to Release FY2025 Q3 Earnings on October 22 After-Market (BJT)

Lummy released FY2025 Q2 earnings on August 21 After-Market (BJT), actual revenue CNY 178.8 M, actual EPS CNY -0.0167

Lummy released FY2025 Semi-Annual earnings on August 21 After-Market (BJT), actual revenue CNY 377.19 M, actual EPS CNY -0.0297

Lummy FY2025 Semi-Annual Earnings Release on August 22, 2025 (BJT)

Laiming Pharmaceutical's generic drug Baloxavir Marboxil enters BE trial phase

Limei Pharmaceutical Receives Acetaminophen Granules 'Drug Registration Certificate'

HighTide Therapeutics and Others Seen as Investment Opportunities

Limei Pharmaceutical Receives Approval for Naloxone Hydrochloride Injection Supplement Application

Laimay Pharmaceutical's New Drug Approvals and Market Strategies

Laimay Pharmaceutical Q1 2025 Revenue Growth and Expanded Net Loss

Lummy released FY2025 Q1 earnings on April 23 After-Market BJT, actual revenue CNY 198.4 M, actual EPS CNY -0.013

Lummy FY2025 Q1 Earnings Release Scheduled for April 24 After-Market BJT

Chongqing Laimei Pharmaceutical's Clindamycin Phosphate Injection Passes Consistency Evaluation

300006

Lummy announced that the company participated in the bidding for the 11th batch of national centralized drug procurement, with the product Nicorandil tablets expected to be selected, with a proposed selection price of 2.95 yuan/box. The proposed selection quantity and the provinces to be supplied will be subject to final data. This product obtained its registration certificate in 2025 and has not yet been sold as of now. If the procurement contract is signed and implemented subsequently, it will promote product sales and market expansion, enhancing brand influence. However, there are uncertainties regarding the signing of the procurement contract and other subsequent matters

Zhitong

Lummy: Product Nicorandil tablets intend to be selected for the 11th batch of national drug procurement

According to the Zhitong Finance APP, Lummy released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 581 million yuan, a year-on-year decrease of 4.06%. The net loss attributable to shareholders of the listed company was 45.9172 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 48.379 million yuan. The basic loss per share was 0.0435 yuan

Lummy Pharmaceuticals released its performance for the first three quarters, with a net loss attributable to the parent company of 45.9172 million yuan

002755

300111

300436

688428

09969

The pharmaceutical sector fluctuated and strengthened, with ASK PHARM hitting the limit up, SUNFLOWER rising over 13%, and Cosunter, Xinlitai, Lummy, and INNOCARE among the top gainers

ASK PHARM

SUNFLOWER

Cosunter

InnoCare Pharma

INNOCARE

The pharmaceutical sector fluctuates and strengthens, ASK PHARM hits the limit up

According to the Zhitong Finance APP, Lummy announced that the company has received the Drug Registration Certificates for two medications: Nicorandil Tablets (Specification: 5mg) and Ketorolac Tromethamine Injection (Specification: 1ml: 30mg) approved by the National Medical Products Administration. The announcement indicates that Nicorandil Tablets are used for the treatment of angina pectoris. Ketorolac Tromethamine Injection is suitable for the short-term treatment of moderate to severe acute postoperative pain

Lummy obtained two drug registration certificates

Lummy announced that its controlling shareholder, Zhongheng Group, received a notice from its indirect controlling shareholder, Guangtou Group, stating that there will be a change in Guangtou Group's equity structure. The Guangxi State-owned Assets Supervision and Administration Commission will transfer its 33% stake in Guangtou Group to Guangxi Guokong Group without compensation. After this change, Zhongheng Group will still be the controlling shareholder, and the Guangxi State-owned Assets Supervision and Administration Commission will remain the actual controller, with no substantial impact on the company's operations and production activities

Lummy: The equity structure of the indirect controlling shareholder is expected to change

600513

603590

600222

688166

The innovative drug concept has recently strengthened repeatedly, with Lummy hitting a 20% limit up. Previously, JLPC and Konruns also hit the limit up, while Yahui Pharmaceutical rose over 15%. Guangshengtang, Guanhao Biological, Taloph, and BrightGene all rose over 5%

JLPC

Konruns

Taloph

BrightGene

The concept of innovative drugs has repeatedly strengthened, with Lummy and other stocks hitting the daily limit

Lummy recently announced that its generic drug Mabalosavir tablets have obtained ethical approval and officially entered the bioequivalence testing phase. This medication is used to treat influenza, featuring a unique mechanism of action that can take effect early in the flu and only requires a single dose to effectively suppress the virus within 24 hours, shorten the infectious period, reduce the duration of symptoms, and remains effective for patients resistant to Oseltamivir

Lummy's generic drug Mabalosavir tablets have obtained ethical approval

Lummy recently obtained the azithromycin granules drug registration certificate issued by the National Medical Products Administration. This medication is suitable for various infections, including bronchitis, pneumonia, skin and soft tissue infections, acute otitis media, sinusitis, pharyngitis, tonsillitis, and genital infections caused by Chlamydia trachomatis

Lummy has obtained the registration certificate for Azithromycin granules

002490

00568

HighTide Therapeutics and two other Asian penny stocks are highlighted as potential investment opportunities amidst fluctuating global trade policies and easing inflation. HighTide, a biopharmaceutical company, has shown promising Phase 3 trial results for its diabetes treatment, despite being pre-revenue. Shandong Molong Petroleum faces financial challenges but maintains a positive cash runway. Chongqing Lummy Pharmaceutical has improved its debt profile but reported a net loss. These stocks reflect the volatility and potential of penny stocks in the Asian market.

Simplywall

Shandong Molong

SHANDONG MOLONG

HighTide Therapeutics And 2 Other Asian Penny Stocks To Watch Closely

300511

688331

09995

603882

300204

The cell immunotherapy sector saw a short-term surge, with Staidson BioPharm rising over 10%, followed by XUERONG, RemeGen, Kingmed Diagnostics, Lummy, and Heyuan Bio

XUERONG

RemeGen

REMEGEN

Kingmed Diagnostics

Staidson BioPharm

OBiO Tech

The cellular immunotherapy sector has seen a short-term surge, with Staidson BioPharm rising over 10%

Lummy(300006.SZ)